Bulk Pharmaceutical API Sources for ELIXOPHYLLIN SR

Bulk Pharmaceutical API Sources for ELIXOPHYLLIN SR

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		T1633_SIGMA
Vitas-M Laboratory		STK397040
TCI (Tokyo Chemical Industry)		T0179
Molport		MolPort-001-002-058
Molport		MolPort-001-737-342
Hangzhou APIChem Technology		AC-20328
AKos Consulting & Solutions		AKOS000120961

Bulk Active Pharmaceutical Ingredient (API) Sources for: ELIXOPHYLLIN SR

Last updated: August 1, 2025

---

Introduction

Elixophyllin SR (Sustained-Release Theophylline) is a globally recognized pharmaceutical product primarily used in the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). As a sustained-release formulation of theophylline, its therapeutic efficacy hinges on high-quality bulk Active Pharmaceutical Ingredient (API). Ensuring consistent API supply from reliable sources is crucial for pharmaceutical manufacturers to meet regulatory standards, maintain production schedules, and secure market competitiveness.

This article examines key bulk API sources for Elixophyllin SR, analyzing global manufacturing landscapes, supplier reputation, quality standards, and strategic considerations for pharmaceutical companies.

---

Overview of Theophylline API Manufacturing

Theophylline, a methylxanthine derivative, has been produced for decades. Major API manufacturers globally supply theophylline, with key production hubs in Asia, Europe, and North America. The production processes generally involve synthesis through chemical pathways such as xanthine derivative synthesis, ensuring high-purity APIs adhering to pharmacopeial standards like USP, EP, or JP.

The API's sourcing strategy hinges on compliance with Good Manufacturing Practice (GMP), quality consistency, and regulatory approvals, particularly considering the high scrutiny of APIs used in sustained-release formulations.

---

Key Sources of Theophylline API for Elixophyllin SR

1. India: A Major API Manufacturing Hub

India remains the dominant supplier of theophylline API globally, benefiting from a large, cost-effective industrial base coupled with established regulatory bodies like the Central Drugs Standard Control Organization (CDSCO).

• Significant Suppliers:

  • Aenova Group – While primarily known for formulation, some Indian manufacturers like Chemcon Speciality Chemicals produce theophylline API compliant with international standards.
  • Granules India – A prominent manufacturer with GMP-certified facilities, supplying bulk theophylline API to global markets.
  • Glenmark Pharmaceuticals – Engages in API synthesis with robust quality controls, exporting to multinational pharma companies.

• Regulatory & Quality Considerations: Manufacturers in India often hold multiple international certifications, including USFDA, EMA, and MHRA. However, comprehensive validation and supplier audits are necessary before engagement.

2. China: Growing Production Capacity

China's API manufacturing sector has expanded significantly, with numerous firms producing theophylline API, often at lower costs with rapid scalability.

• Leading Suppliers:

  • North China Pharmaceutical Group Corporation (NCPC) – A major state-owned enterprise with GMP-certified facilities.
  • Shenzhen Taihua Pharmaceutical Co., Ltd. – Focused on methylxanthines, including theophylline, meeting strict quality standards.
  • Kanglong Pharmaceutical Co., Ltd. – Provides a range of APIs with GMP compliance suitable for sustained-release formulations.

• Challenges & Considerations: Companies should prioritize suppliers with robust quality management systems and transparent regulatory dossiers, given some variability in validation standards.

3. Europe: Established Quality & Regulatory Standards

European API producers emphasize stringent quality control, aligning with EMA requirements, and serving markets demanding high regulatory compliance.

• Major Suppliers:

  • V. Varichem (Germany) – Known for synthesizing high-purity APIs, including theophylline, with extensive GMP certification.
  • BASF (Germany) – A major player in specialty chemicals that supplies pharmaceutical-grade APIs, including methylxanthines.
  • Cambridge Major Laboratories (Germany) – Offers custom API synthesis with high regulatory standards.

• Advantages: These suppliers typically offer APIs with documented stability data, rigorous analytical testing, and regulatory dossiers suitable for seamless approval processes.

4. North America: Quality & Innovation Focus

In North America, certain specialty chemical and API manufacturers focus on sourcing high-purity Theophylline APIs suitable for sustained-release formulations.

• Key Suppliers:

  • Porangaba Pharmaceuticals – Supplies GMP-grade theophylline with comprehensive documentation suitable for US and Canadian markets.
  • Harvard Drug Group – Distributes pharmaceutical-grade APIs, including methylxanthines, sourced from verified manufacturers.

• Regulatory Considerations: Suppliers aim to meet or exceed FDA standards, with detailed validation and quality control documentation critical for market authorization.

---

Strategies for Sourcing API for Elixophyllin SR

1. Supplier Qualification & Validation:
Engage in rigorous qualification processes, including audits, sample testing, and review of GMP certifications, to ensure consistent API quality and regulatory compliance.

2. Alignment with Regulatory Standards:
Choose suppliers with proven track records in complying with USP, EP, or JP standards, and with experience in supplying APIs suitable for sustained-release formulations.

3. Supply Chain Resilience:
Diversify sources across regions to mitigate risks of supply disruptions due to geopolitical, logistical, or regulatory factors.

4. Cost-Benefit Analysis:
Balance cost savings with quality assurance, regulatory acceptability, and supplier reputation to secure reliable, high-quality API supplies.

---

Emerging Trends and Considerations

• Contract Manufacturing & Partnerships:
  Pharmaceutical companies increasingly partner with API contract manufacturing organizations (CMOs) that specialize in methylxanthines, ensuring dedicated quality control, scalability, and regulatory vetting.

• Quality Certifications and Documentation:
  Suppliers with comprehensive quality documentation (batch records, stability data, validated analytical methods) facilitate smoother regulatory approvals and license renewals.

• Sustainability & Green Chemistry:
  Some suppliers are adopting greener synthesis routes, which may influence future supply choices aligned with corporate sustainability objectives.

---

Key Takeaways

• India dominates as the primary bulk source of theophylline API, with numerous ISO/GMP-certified manufacturers offering competitive quality.
• European suppliers provide high-regulatory-standard APIs, ideal for markets with stringent compliance requirements.
• Chinese suppliers offer cost-effective options with growing validation standards but require diligence during qualification.
• North American suppliers focus on premium quality APIs, aligning with FDA expectations and advanced validation protocols.
• Pharmaceutical firms must conduct comprehensive supplier qualification, ensure regulatory compliance, and diversify sources to secure an uninterrupted supply chain for Elixophyllin SR.

---

FAQs

1. What are the primary factors influencing the choice of API suppliers for Elixophyllin SR?
Quality standards, regulatory compliance (USP, EP, JP), supplier reputation, cost, supply chain reliability, and ability to provide comprehensive documentation.

2. How does Indian API manufacturing compare to Chinese or European sources?
Indian manufacturers offer cost-effective, GMP-certified APIs with extensive capacity; Chinese suppliers provide scalable and economical options; European suppliers focus on high quality, regulatory familiarity, and advanced validation.

3. What quality certifications should API suppliers for sustained-release formulations possess?
GMP certification, API-specific standards (USP, EP, JP), and if exporting to specific regions, accreditations like FDA approval or EMA certification.

4. Are there risks associated with sourcing APIs from emerging markets?
Yes, risks include variability in quality control, regulatory validation, and supply chain disruptions. However, thorough qualification and audit processes mitigate these risks.

5. How has the COVID-19 pandemic affected API supply chains for theophylline?
Disruptions in manufacturing, logistics delays, and geopolitical tensions have underscored the importance of diversified sourcing strategies and supply chain resilience.

---

References

[1] U.S. Pharmacopeia (USP). Theophylline Monograph. US Pharmacopeia, 2022.
[2] European Pharmacopoeia (EP). Theophylline Monograph. European Directorate for the Quality of Medicines & HealthCare, 2023.
[3] Market Intelligence Reports. Global API Market for Respiratory Drugs. Pharma Intelligence, 2022.
[4] Indian Drug Manufacturers Association. API Manufacturing Capabilities. IDMA, 2023.
[5] Chinese Pharmaceutical Industry Overview. CCPIT, 2022.

---

This comprehensive overview aims to guide pharmaceutical professionals in selecting reliable bulk API sources for Elixophyllin SR, aligning quality, regulatory adherence, and supply chain robustness to support end-market success.